Document is current
Any future updates will be listed below
-
Authors
Tonse, Raees
Ramamoorthy, Venkataraghavan
Rubens, Muni
Saxena, Anshul
McGranaghan, Peter
Veledar, Emir
Hall, Matthew D.
Chuong, Michael D.
Ahluwalia, Manmeet S.
Mehta, Minesh P.
Kotecha, Rupesh
- License Information
-
More Information
Article History
Received: 10 January 2022
Accepted: 28 February 2022
First Online: 14 March 2022
Competing interests
: R. Tonse, M. Rubens, V. Ramamoorthy, A. Saxena, E. Veledar, P. McGranaghan: None. M. Hall: Honorarium from Accuray, Inc. Proton Collaborative Group Executive Committee Institutional Representative and Voting Member, Miami Cancer Institute (unpaid). Grant Funding: Live Like Bella Pediatric Cancer Research Initiative, Florida Department of Health Grant 8LA04. M. Chuong: Honorarium from Accuray, Inc., ViewRay Inc., Sirtex Inc. Advisory board for ViewRay, Inc. Research funding from ViewRay, Inc., Novocure, Inc., AstraZeneca, Inc. M. S. Ahluwalia: Receipt of grants/research supports: Astrazeneca, BMS, Bayer, Incyte, Pharmacyclics, Novocure, Mimivax, Merck. Receipt of honoraria or consultation fees: Bayer, Novocure, Kiyatec, Insightec, GSK, Nuvation, Cellularity, Apollomics. Stock shareholder: Doctible, Mimivax, Cytodyn. M. P. Mehta: Consulting for Karyopharm, Sapience, Zap, Mevion. Board of Directors: Oncoceutics. R. Kotecha: Honoraria from Accuray Inc., Elekta AB, Viewray Inc., Novocure Inc., Elsevier Inc. Institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, Astrazeneca, Exelixis, Viewray Inc.
